Please see enclosed pdf.

Today, 5 December 2024, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted:

The divestment is part of a strategic initiative to simplify business operations and improve profitability in the Advanced Wound Care business area.

On 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD)¹ policy regarding skin substitute grafts/cellular and tissue-based products for the treatment of Diabetic Foot Ulcers (DFUs) and venous leg ulcers (VLUs) in the Medicare population.

The Annual General Meeting of Coloplast A/S will be held on
Thursday, 5 December 2024 at 3:30 pm CET
at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark.
The notice of the Annual General Meeting is enclosed.

Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24

2023/24

Coloplast expands Executive Leadership Team

Today, the Board of Directors have decided to expand the Coloplast Executive Leadership Team (ELT) with immediate effect.

Tuesday, 5 November 2024 at 11.00 – 12.00 CET
In connection with the publication of Coloplast's interim financial results for FY 2023/24 the company will host a conference call to present the financial results and answer questions from investors and financial analysts.
A presentation will be available on Coloplast's website approximately 1 hour before the conference call.
Please note that the webcast of the conference call will be available during and after the event.

Please see enclosed pdf.